Chapter 3 - The Reconstruction of Treason
By 4:00 AM, the toxicology report arrived on Ruth’s secure tablet.
The substance was Compound-889, an experimental neuro-sedative currently in Phase I trials at our secondary facility in Boston. It was tasteless, odorless, and designed to cross the blood-brain barrier rapidly to induce a state of highly suggestible compliance before causing a deep, amnesiac sleep.
“It’s a restricted substance,” Daniel said, throwing a stack of digital manifests onto the table in the hospital’s private waiting room. “Only three people had the clearance codes to check out a sample from the Boston vault this week.”
I looked at the list.
Dr. Aris Thorne (Lead Researcher)
Evelyn Vane (Myself)
Grant Whitmore (using my forged digital signature)
“He forged my signature to authorize the transport of a chemical weapon to our own headquarters,” I said, a dark laugh escaping my throat. “He’s not just greedy. He’s sloppy.”
“He was sloppy because he didn’t think he’d ever have to answer for it,” Ruth explained. “If you had signed the emergency transfer papers while under the influence of Compound-889, he would have assumed total operational control of the company by morning. By the time you recovered, any investigation would have been shut down by the new CEO—him.”
We spent the next four hours piecing together the digital trail. Daniel’s cybersecurity team had spent the night downloading the encrypted communications from Vanessa Hale’s company-issued phone. Because she had used the corporate network to send her messages, she had no expectation of privacy under her employment contract.
What we found was a map of a betrayal that went far deeper than a simple office affair.
[Vanessa Hale] 11:24 PM: "Is the Boston delivery secure?"
[Grant Whitmore] 11:26 PM: "Yes. Evelyn thinks it's a new batch of heart medication sample. She'll take the toast. Make sure her glass is the one with the blue crystal stem."
[Vanessa Hale] 11:28 PM: "And the Aegis deal?"
[Grant Whitmore] 11:30 PM: "Once she signs the transfer, Aegis buys our proprietary gene-editing patent for $120 million. We split the offshore transfer. She won't have the mental capacity to sue us by the time the ink dries."
My chest tightened. Aegis Pharma.
Our biggest competitor. The company that had tried to hostile-takeover Whitmore Biologics twice in the last decade. Grant wasn't just trying to take over my company; he was planning to dismantle it from the inside out and sell our crown jewel—the gene-editing patent my mother had spent her life developing—to our bitterest enemy.
May you like
“He wanted to ruin me,” I said, my voice barely a whisper. “He didn’t just want the money. He wanted to wipe out my mother’s legacy.”
“He won’t,” Daniel said, his voice firm as he placed a cup of black coffee in front of me. “The sun is coming up, Evelyn. It’s time to get dressed. The board meets in three hours.”
